A tumor vasculature targeted liposome delivery system for combretastatin A4: Design, characterization, and in vitro evaluation

AAPS PharmSciTech

Volumn 7, Issue 2, 2006, Pages

  Nallamothu, Ramakrishna ^a,d   Wood, George C ^a   Pattillo, Christopher B ^b   Scott, Robert C ^b   Kiani, Mohammad F ^b,c   Moore, Bob M ^a   Thoma, Laura A ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b Temple University   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NONE   (United States)

Author keywords

Combretastatin A4; Liposome characterization; Targeted liposome delivery system; Tumor vasculature targeting

Indexed keywords

ARGININE; ASPARTIC ACID; CHOLESTEROL; COMBRETASTATIN A4; GLYCINE; LIGAND; LIPOSOME; MACROGOL; MALEIMIDE; PHOSPHATIDYLCHOLINE; VITRONECTIN RECEPTOR; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ARGINYL-GLYCYL-ASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; COMBRETASTATIN A 4; COMBRETASTATIN A-4; DRUG CARRIER; OLIGOPEPTIDE; STILBENE DERIVATIVE;

ARTICLE; BINDING AFFINITY; CELL CULTURE; CELL SURFACE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG TARGETING; ELECTRON MICROSCOPY; ENDOTHELIUM CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDRATION; IN VITRO STUDY; LIPID MEMBRANE; TUMOR CELL; TUMOR VASCULARIZATION; UMBILICAL VEIN; CHEMISTRY; EVALUATION; METABOLISM; METHODOLOGY;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELLS, CULTURED; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; HUMANS; LIPOSOMES; OLIGOPEPTIDES; STILBENES;

EID: 33645791307     PISSN: 15309932     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt070231     Document Type: Article

References (32)

1. Lasic DD, Papahadjopoulos D. Medical Applications of Liposomes. Amsterdam, The Netherlands: Elsevier, 1998.
2. Forssen EA, Coulter DM, Proffitt RT. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res. 1992;52:3255-3261.
3. Park JW, Hong K, Kirpotin DB, Meyer O, Papahadjopoulos D, Benz CC. Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Lett. 1997; 118:153-160.
4. Stephenson SM, Low PS, Lee RJ. Folate receptor-mediated targeting of liposomal drugs to cancer cells. Methods Enzymol. 2004; 387:33-50.
5. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 1997;57:1829-1834.
6. Young SL, Chaplin DJ. Combretastatin A4 phosphate: background and current clinical status. Expert Opin Investig Drugs. 2004;13:1171-1182.
7. Hynes RO. A reevaluation of integrins as regulators of angiogenesis. Nat Med. 2002;8:918-921.
8. Kumar CC, Armstrong L, Yin Z, et al. Targeting integrins alpha v beta 3 and alpha v beta 5 for blocking tumor-induced angiogenesis. Adv Exp Med Biol. 2000;476:169-180.
9. Haubner R, Gratias R, Diefenbach B, Goodman SL, Jonczyk A, Kessler H. Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin alpha v beta 3 antagonists. J Am Chem Soc. 1996;118:7461-7472.
10. Pattillo CB, Sari-Sarraf F, Nallamothu R, Moore BM, Wood GC, Kiani MF. Targeting of the antivascular drug combretastatin to irradiated tumors results in tumor growth delay. Pharm Res. 2005;22:1117-1120.
11. Pettit GR, Singh SB, Boyd MR, et al. Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a). J Med Chem. 1995;38:1666-1672.
12. Hope MJ, Bally NO, Webb G, Cullis PR. Production of large unilamellar vesicles by a rapid extrusion procedure: characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim Biophys Acta. 1985;812:55-65.
13. New RRC, Black CDV, Parker RJ, Puri A, Scherphof GL. Liposomes in biological systems. In: New RRC, ed. Liposomes: A Practical Approach. Oxford, UK: IRL Press Ltd; 1993:221-252.
14. Prabhakarpandian B, Goetz DJ, Swerlick RA, Chen X, Kiani MF. Expression and functional significance of E-selectin on cultured endothelial cells in response to ionizing radiation. Microcirculation. 2001;8:355-364.
15. Gabizon A, Chemla M, Tzemach D, Horowitz AT, Goren D. Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines. J Drug Target. 1996;3:391-398.
16. Kirby C, Clarke J, Gregoriadis G. Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem J 1980;186:591-598.
17. Semple SC, Chonn A, Cullis PR. Influence of cholesterol on the association of plasma proteins with liposomes. Biochemistry. 1996;35:2521-2525.
18. Torchilin VP, Omelyanenko VG, Papisov MI, et al. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim Biophys Acta. 1994; 1195:11-20.
19. Hansen CB, Kao GY, Moase EH, Zalipsky S, Allen TM. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim Biophys Acta. 1995;1239:133-144.
20. Martin FJ, Papahadjopoulos D. Irreversible coupling of immunoglobulin fragments to preformed vesicles: an improved method for liposome targeting. J Biol Chem. 1982;257:286-288.
21. Allen TM, Brandeis E, Hansen CB, Kao GY, Zalipsky S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta. 1995;1237:99-108.
22. Maurer N, Fenske DB, Cullis PR. Developments in liposomal drug delivery systems. Expert Opin Biol Ther 2001;1:923-947.
23. Rouser G, Fkeischer S, Yamamoto A. Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids. 1970;5:494-496.
24. Kawahara K, Sekiguchi A, Kiyoki E, et al. Effect of TRX-liposomes size on their prolonged circulation in rats. Chem Pharm Bull (Tokyo). 2003;51:336-338.
25. Bredehorst R, Ligler FS, Kusterbeck AW, Chang EL, Gaber BP, Vogel CW. Effect of covalent attachment of immunoglobulin fragments on liposomal integrity. Biochemistry. 1986;25:5693-5698.
26. Spragg DD, Alford DR, Greferath R, et al. Immunotargeting of liposomes to activated vascular endothelial cells: a strategy for site-selectivc delivery in the cardiovascular system. Proc Natl Acad Sci USA. 1997;94:8795-8800.
27. Cheresh DA. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc Natl Acad Sci USA. 1987;84:6471-6475.
28. Czyz M, Cierniewski CS. Selective Sp1 and Sp3 binding is crucial for activity of the integrin alpha v promoter in cultured endothelial cells. Eur J Biochem. 1999;265:638-644.
29. Koning GA, Morselt HW, Velinova MJ, et al. Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells. Biochim Biophys Acta. 1999; 1420:153-167.
30. Goren D, Horowitz AT, Zalipsky S, Woodlc MC, Yarden Y, Gabizon A. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. Br J Cancer. 1996;74:1749-1756.
31. Kirpotin D, Park JW, Hong K, et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry. 1997;36:66-75.
32. Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995;55:3752-3756.